Evidence map›Paper›PMID 40262080›Full record

ArticlePLoS pathogens2025

Quantifying prevalence and risk factors of HIV multiple infection in Uganda from population-based deep-sequence data.

Michael A Martin, Andrea Brizzi, Xiaoyue Xi, Ronald Moses Galiwango, Sikhulile Moyo, Deogratius Ssemwanga, Alexandra Blenkinsop, Andrew D Redd, Lucie Abeler-Dörner, Christophe Fraser and 10 more

Abstract read
In one paragraph

Article in PLoS pathogens, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Michael A MartinDepartment of Pathology, Johns Hopkins School of Medicine, Baltimore, Maryland, United States of America.ORCID https://orcid.org/0000-0002-9689-4066
Andrea BrizziDepartment of Mathematics, Imperial College London, London, United Kingdom.
Xiaoyue XiDepartment of Mathematics, Imperial College London, London, United Kingdom.
Ronald Moses GaliwangoRakai Health Sciences Program, Kalisizo, Uganda.
Sikhulile MoyoBotswana Harvard AIDS Institute Partnership, Botswana Harvard HIV Reference Laboratory, Gaborone, Botswana.
Deogratius SsemwangaMedical Research Council/Uganda Virus Research Institute and London School of Hygiene and Tropical Medicine Uganda Research Unit, Entebbe, Uganda.
Alexandra BlenkinsopDepartment of Mathematics, Imperial College London, London, United Kingdom.
Andrew D ReddDepartment of Medicine, Johns Hopkins School of Medicine, Baltimore, Maryland, United States of America.
Lucie Abeler-DörnerPandemic Sciences Institute, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.
Christophe FraserPandemic Sciences Institute, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.
Steven J ReynoldsRakai Health Sciences Program, Kalisizo, Uganda.
Thomas C QuinnRakai Health Sciences Program, Kalisizo, Uganda.
Joseph KagaayiRakai Health Sciences Program, Kalisizo, Uganda.
David BonsallWellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.
David SerwaddaRakai Health Sciences Program, Kalisizo, Uganda.
Gertrude NakigoziRakai Health Sciences Program, Kalisizo, Uganda.
Godfrey KigoziRakai Health Sciences Program, Kalisizo, Uganda.
M Kate GrabowskiDepartment of Pathology, Johns Hopkins School of Medicine, Baltimore, Maryland, United States of America.
Oliver RatmannDepartment of Mathematics, Imperial College London, London, United Kingdom.
with the PANGEA-HIV Consortium and the Rakai Health Sciences Program

Funding

Vaccine Response and Immunotherapeutics SWGP30AI094189 · NIAID · JOHNS HOPKINS UNIVERSITY · PI Anna Palmer Durbin · 2012 to 2026
$67.0M
International Center for Excellence in Research (ICER) in Uganda: Impact of ARVsZIAAI001040 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI REYNOLDS, STEVEN · 2009 to 2025
$23.5M
Circumcision: HIV/STIs and behaviors in a RCT and post-RCT surveillance; RakaiU01AI075115 · NIAID · JOHNS HOPKINS UNIVERSITY · PI GRAY, RONALD H · 2007 to 2011
$9.3M
Epidemiology and Impact of the HIV, NCD, and Urbanization Syndemic in AfricaR01HL152813 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI CHANG, LARRY WILLIAM · 2021 to 2025
$7.8M
ARV effects on HIV epidemiology &behaviors Rakai UgandaR01HD050180 · NICHD · JOHNS HOPKINS UNIVERSITY · PI WAWER, MARIA J · 2005 to 2009
$7.8M
Structural and Social Transitions Among Adolescents in Rakai (SSTAR)R01HD091003 · NICHD · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI SANTELLI, JOHN S. · 2017 to 2021
$3.7M
The role of penile bacteria and inflammation in HIV susceptibility; Rakai, UgandaR01AI123002 · NIAID · GEORGE WASHINGTON UNIVERSITY · PI LIU, CINDY · 2016 to 2020
$3.3M
Enhanced Provision of Male Circumcision for HIV Prevention, Rakai, UgandaU01AI100031 · NIAID · JOHNS HOPKINS UNIVERSITY · PI GRAY, RONALD H · 2012 to 2014
$3.2M
Evaluating Demand Generation (Stylish Man) for HIV/Family Planning Services RakaiR01AI114438 · NIAID · JOHNS HOPKINS UNIVERSITY · PI WAWER, MARIA J · 2014 to 2017
$3.0M
Genital Anaerobes, Inflammation and HIV Risk; RakaiR01AI087409 · NIAID · JOHNS HOPKINS UNIVERSITY · PI GRAY, RONALD H, PRICE, LANCE BRADLEY · 2010 to 2012
$2.5M
Long-term impact of universal treatment and dolutegravir on population HIV virologic and incidence outcomes in Africa: The LONGVIEW StudyR01AI155080 · NIAID · JOHNS HOPKINS UNIVERSITY · PI GRABOWSKI, MARY KATHRYN · 2021 to 2024
$2.5M
Hard-to-Reach Populations: Implications for Ending the AIDS EpidemicR01AI143333 · NIAID · JOHNS HOPKINS UNIVERSITY · PI CHANG, LARRY WILLIAM · 2019 to 2022
$2.4M
FIC NIH HHS D43 TW009578FIC NIH HHS D43 TW010557Gates Foundation INV-007573Gates Foundation INV-035619Intramural NIH HHS ZIA AI001040NHLBI NIH HHS R01 HL152813NIAID NIH HHS K01 AI125086NIAID NIH HHS K25 AI114461NIAID NIH HHS L30 AI178824NIAID NIH HHS P30 AI094189NIAID NIH HHS R01 AI087409NIAID NIH HHS R01 AI110324NIAID NIH HHS R01 AI114438NIAID NIH HHS R01 AI123002NIAID NIH HHS R01 AI128779NIAID NIH HHS R01 AI143333NIAID NIH HHS R01 AI155080NIAID NIH HHS R21 AI145682NIAID NIH HHS U01 AI075115NIAID NIH HHS U01 AI100031NICHD NIH HHS R01 HD050180NICHD NIH HHS R01 HD070769NICHD NIH HHS R01 HD091003
6 · The paper itself

Abstract

People living with HIV can acquire secondary infections through a process called superinfection, giving rise to simultaneous infection with genetically distinct variants (multiple infection). Multiple infection provides the necessary conditions for the generation of novel recombinant forms of HIV and may worsen clinical outcomes and increase the rate of transmission to HIV seronegative sexual partners. To date, studies of HIV multiple infection have relied on insensitive bulk-sequencing, labor intensive single genome amplification protocols, or deep-sequencing of short genome regions. Here, we identified multiple infections in whole-genome or near whole-genome HIV RNA deep-sequence data generated from plasma samples of 2,029 people living with viremic HIV who participated in the population-based Rakai Community Cohort Study (RCCS). We estimated individual- and population-level probabilities of being multiply infected and assessed epidemiological risk factors using the novel Bayesian deep-phylogenetic multiple infection model (deep - phyloMI) which accounts for bias due to partial sequencing success and false-negative and false-positive detection rates. We estimated that between 2010 and 2020, 4.09% (95% highest posterior density interval (HPD) 2.95%-5.45%) of RCCS participants with viremic HIV multiple infection at time of sampling. Participants living in high-HIV prevalence communities along Lake Victoria were 2.33-fold (95% HPD 1.3-3.7) more likely to harbor a multiple infection compared to individuals in lower prevalence neighboring communities. This work introduces a high-throughput surveillance framework for identifying people with multiple HIV infections and quantifying population-level prevalence and risk factors of multiple infection for clinical and epidemiological investigations.

Indexed as

CoinfectionHIV-1HIV InfectionsSuperinfectionAdultCohort StudiesFemaleHigh-Throughput Nucleotide SequencingHumansMaleMiddle AgedPhylogenyPrevalenceRisk FactorsRNA, ViralUgandaRNA, Viral

Identifiers

PMID40262080
PMCPMC12055032

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.